## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.91 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($91.56)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Boston Scientific (BSX) Stock After Hours on Dec. 17, 2025: Analysts Stay Bullish as Shares Close Higher — What to Watch Before Thursday’s Open**
- Source: ts2.tech | 20251218T023012 | Bullish | Relevance: 100%
- Boston Scientific (BSX) shares closed higher on December 17, 2025, outperforming the broader market downturn, with analysts largely maintaining bullish ratings and price targets significantly above the current share price. The stock showed modest gains in after-hours trading, indicating investors positively received recent analyst updates. Investors are now looking to Thursday morning's macro data, specifically the November 2025 U.S. CPI release and weekly initial jobless claims, which could influence market sentiment and BSX's performance.

**2. Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?**
- Source: Finviz | 20251217T160745 | Neutral | Relevance: 100%
- This article evaluates Boston Scientific (BSX) based on Wall Street analyst recommendations and the Zacks Rank system. While BSX has a Strong Buy to Buy average brokerage recommendation, the article cautions against relying solely on these recommendations due to potential analyst bias. It suggests using the Zacks Rank, which is based on earnings estimate revisions and has a strong track record, as a more effective tool for investment decisions.

**3. UBS reiterates Buy rating on Boston Scientific stock with $140 price target**
- Source: Investing.com | 20251217T152938 | Bullish | Relevance: 100%
- UBS has reiterated its Buy rating and $140 price target for Boston Scientific (NYSE:BSX), despite a recent stock dip, citing the company's strong revenue growth and reasonable valuation. Analyst Danielle Antalffy projects upside potential, particularly from the WATCHMAN device and Electrophysiology division, which are expected to drive double-digit sales growth. Other firms like Canaccord Genuity, Leerink Partners, and TD Cowen also maintain positive outlooks, reinforcing confidence in Boston Scientific's financial performance and strategic initiatives.

**4. Gradient Investments LLC Has $22.49 Million Stock Holdings in Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20251217T093030 | Bullish | Relevance: 100%
- Gradient Investments LLC increased its stake in Boston Scientific (NYSE:BSX) by 5.5% to 230,372 shares, valued at $22.49 million, during the third quarter. Boston Scientific exceeded Q3 earnings estimates with an EPS of $0.75 and revenue of $5.07 billion, and analysts currently hold a consensus "Buy" rating with a $125.15 price target. Despite insider selling, institutional ownership remains high at 89.07%.

**5. Boston Scientific Corporation $BSX Shares Acquired by Assenagon Asset Management S.A.**
- Source: MarketBeat | 20251217T080824 | Bullish | Relevance: 100%
- Assenagon Asset Management S.A. increased its stake in Boston Scientific Corporation (NYSE:BSX) by 9.1% in the third quarter of 2025, acquiring 243,100 additional shares. The medical equipment provider also reported strong Q3 earnings, beating analyst estimates with $0.75 EPS and $5.07 billion in revenue, and issued optimistic guidance for FY2025 and Q4 2025. Wall Street analysts maintain a positive outlook, with most rating BSX as a "Buy" and a consensus price target of approximately $125.15.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $120 | $130 | -8% |
| 2025-12-17 | Canaccord Genui | $131 | $132 | -1% |
| 2025-12-17 | RBC Capital | $130 | $125 | +4% |
| 2025-11-21 | BTIG | $132 | $132 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | Canaccord Genui | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |
| 2025-11-21 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 9 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +6.0% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Balance sheet: $2.6B free cash flow. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $142.5B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 27.7 |
| Current P/E | 31.7 |
| YoY Growth | 14.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -5.6% to 0.4% (+6.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.6pp (needs >4.0% for momentum thesis). MRS_5 at 2.6% confirms short-term momentum alignment. Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 48. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.38% (CS: 44) | Neutral |
| RSI_14 | 48.4 | Neutral |
| MACD Histogram | -0.09 | Bearish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 0.975x | Below |
| vs SMA200 | 0.952x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $96.12
- **Stop Loss:** $91.56 (4.7% risk)
- **Target:** $105.24 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 208
- **Position Value:** $19,992.96
- **Portfolio %:** 19.99%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*